

Table 1: Summary of the included studies in the review:

Study	No. of patients	No. of patients (Non-Severe) illness	No. of patients (Severe illness)	L count: Non-Severe group (SD)	L count: Severe group (SD)	CRP: Non-Severe group (SD)	CRP: Severe group (SD)	LDH: Non-Severe group (SD)	LDH: Severe group (SD)	D-Dimer: Non-Severe group (SD)	D-Dimer: Severe group (SD)
Peng YD et al	112	96	16	0.99 (0.26)	0.69 (0.27)	38.7 (19.30)	107.8 (15.6)	295 (41.80)	341.6 (50.4)	N.A	N.A
Zhou F et al	191	137	54	1.125 (0.29)	0.625 (0.22)	N.A	N.A	261 (28.59)	518.5 (88.3)	0.63 (0.28)	8.25 (5.68)
Wang D et al	138	102	36	0.9 (0.28)	0.75 (0.23)	N.A	N.A	221.5 (34.65)	442 (84.87)	0.18 (0.13)	0.58 (0.33)
Gao Y et al	43	28	15	1.07 (0.40)	1.20 (0.42)	18.76 (22.20)	39.37 (27.68)	N.A	N.A	0.22 (0.21)	0.55 (0.27)
Wan S et al	135	95	40	1.2 (0.31)	0.8 (0.23)	12.1 (8.45)	92.75 (24.14)	215.5 (23.09)	320.02 (44.6)	0.33 (0.22)	0.68 (0.29)
Young BE et al	18	12	6	1.2 (0.31)	1.175 (0.33)	10.55 (5.24)	69.05 (14.44)	470.25 (133.67)	602 (82.01)	N.A	N.A
Qin C et al	452	166	286	1 (0.27)	0.83 (0.25)	33.58 (14.87)	59.8 (23.67)	N.A	N.A	N.A	N.A
Zhang JJ et al	138	82	56	1.13 (0.33)	0.73 (0.25)	29.75 (12.30)	50.73 (19.20)	N.A	N.A	0.2 (0.21)	0.85 (0.68)
Wang Z et al	69	55	14	1.2 (0.25)	0.65 (0.27)	13.86 (5.72)	79.46 (16.47)	217.25 (26.86)	462.75 (82.38)	N.A	N.A
Guan W et al	1099	926	173	1.05 (0.26)	0.8 (0.34)	N.A	N.A	N.A	N.A	N.A	N.A
Liu W et al	78	67	11	1.01 (0.29)	0.63 (0.32)	14.05 (9.02)	39.225 (14.58)	N.A	N.A	0.51 (0.32)	2.04 (1.95)

L: Lymphocytes count, SD: standard deviation, N.A: non-available